Methotrexate-Ebeve, 10 mg/ml 2 ml

Rheumatoid arthritis, trophoblastic tumors;

Indications

trophoblastic tumors;

Pharmacological effect

Pharmacodynamics

Special instructions

The drug Methotrexate-Ebewe is a cytotoxic drug, so care must be taken when handling it. The drug should be prescribed by a doctor who has experience in the use of methotrexate and is familiar with its properties and characteristics of action. Before prescribing methotrexate, you should ensure that it is possible to determine the plasma concentration of the drug. Taking into account the possibility of severe toxic reactions, including death, the doctor is obliged to inform the patient in detail about the possible risk and necessary precautions.

Active ingredient

Methotrexate

Pregnancy

The use of methotrexate during pregnancy can cause serious malformations of the fetus (increase in the incidence of malformations of the skull, cardiovascular system and limbs by 14 times), therefore the drug Methotrexate-Ebeve is contraindicated during pregnancy.

Contraindications

hypersensitivity to methotrexate and/or any other component of the drug;

Side Effects

According to the World Health Organization (WHO), adverse events are classified according to the frequency of their development as follows: very often (≥1/10), often (from ≥1/100 to Infectious and parasitic diseases often: herpes zoster; uncommon: opportunistic infections, including pneumonia (including fatal); rare: sepsis (including very rarely fatal); very rare: nocardiosis, histoplasmosis, cryptococcosis, hepatitis and disseminated infections caused by herpes simplex virus, infections caused by cytomegalovirus (including pneumonia); frequency unknown: reactivation of hepatitis B virus, hepatitis C.

Interaction

The likelihood of hepatotoxicity from methotrexate increases with regular use of ethanol and concomitant use of other hepatotoxic drugs (for example, azathioprine, leflunomide, sulfasalazine, retinoids). With combination therapy with methotrexate and leflunomide, the incidence of pancytopenia and hepatotoxic effects increases.

Overdose

Symptoms: symptoms associated with inhibition of the hematopoietic system are mainly observed. Treatment: the specific antidote for methotrexate is calcium folinate. It neutralizes adverse toxic effects. In case of accidental overdose, no later than an hour after the administration of methotrexate, calcium folinate is administered (intravenously or intramuscularly) in a dose equal to or higher than the dose of methotrexate.

Manufacturer

Fareva Unterach GmbH, Austria